Is high high-density lipoprotein cholesterol beneficial for premature coronary heart disease? A meta-analysis. 2016

Murtuza Shahid, and Run L Sun, and Yu Liu, and Jin L Bao, and Can X Huang, and Yu Liao, and Shu X Zhou, and Jing F Wang, and Yu L Zhang
Cardiovascular Medicine Department, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.

OBJECTIVE To clarify the association between premature coronary heart disease of patients ≤55 years and high-density lipoprotein cholesterol (HDL-C) plasma levels. METHODS Searches were performed between 2002 and 2013 using PubMed, Web of Science, Science Direct, and Google Scholar. The original articles selected published premature coronary heart disease diagnosed by World Health Organization criteria or via angiograph both in males and females ≤55 years and with plasma HDL-C levels in both the case and control groups. The 'related articles' function and manual searches of the related references was used to broaden the search. The Newcastle-Ottawa Quality Assessment Scale was used to assess the quality of papers. Standard mean difference with 95% confidence interval was used as a measure of the association between HDL and premature coronary heart disease, after pooling data across trials in a random effect model. Sensitivity and subgroup analyses were used to explore sources of heterogeneity and the effect of potential confounders. The influences of publication year, sample size and district were assessed by meta-regression. STATA (version 11.0) was used to conduct all statistical analyses. RESULTS Only 13 case-control studies met the criteria, which included 1775 patients and 1989 controls. The Newcastle-Ottawa Quality Assessment Scale score was about 5-7. A strong association was identified between HDL-C and premature coronary heart disease. The premature coronary heart disease patients had lower levels of HDL-C compared with the controls: standard mean difference = -0.48, 95% confidence interval = -0.71 to -0.26, p < 0.001, pheterogeneity < 0.001. By meta-regression and subgroup analysis, we found publication year might be the source of heterogeneity, but not the main reason for heterogeneity. After removing the heterogeneity of outlier studies, the significant association between low HDL-C levels and premature coronary heart disease was still retained. CONCLUSIONS Low plasma HDL-C levels are positively associated with premature coronary heart disease in patients ≤55 years. As only small sample size case-control studies were found to focus on this age group in the last 10 years, additional population-based cohort studies with large samples are necessary.

UI MeSH Term Description Entries
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D003324 Coronary Artery Disease Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause. Arteriosclerosis, Coronary,Atherosclerosis, Coronary,Coronary Arteriosclerosis,Coronary Atherosclerosis,Left Main Coronary Artery Disease,Left Main Coronary Disease,Left Main Disease,Arterioscleroses, Coronary,Artery Disease, Coronary,Artery Diseases, Coronary,Atheroscleroses, Coronary,Coronary Arterioscleroses,Coronary Artery Diseases,Coronary Atheroscleroses,Left Main Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D050171 Dyslipidemias Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL. Dyslipoproteinemias,Dyslipidemia,Dyslipoproteinemia

Related Publications

Murtuza Shahid, and Run L Sun, and Yu Liu, and Jin L Bao, and Can X Huang, and Yu Liao, and Shu X Zhou, and Jing F Wang, and Yu L Zhang
November 2007, Clinical cardiology,
Murtuza Shahid, and Run L Sun, and Yu Liu, and Jin L Bao, and Can X Huang, and Yu Liao, and Shu X Zhou, and Jing F Wang, and Yu L Zhang
June 1994, Circulation,
Murtuza Shahid, and Run L Sun, and Yu Liu, and Jin L Bao, and Can X Huang, and Yu Liao, and Shu X Zhou, and Jing F Wang, and Yu L Zhang
January 2004, Cardiology in review,
Murtuza Shahid, and Run L Sun, and Yu Liu, and Jin L Bao, and Can X Huang, and Yu Liao, and Shu X Zhou, and Jing F Wang, and Yu L Zhang
January 1991, Annals of the New York Academy of Sciences,
Murtuza Shahid, and Run L Sun, and Yu Liu, and Jin L Bao, and Can X Huang, and Yu Liao, and Shu X Zhou, and Jing F Wang, and Yu L Zhang
September 1991, BMJ (Clinical research ed.),
Murtuza Shahid, and Run L Sun, and Yu Liu, and Jin L Bao, and Can X Huang, and Yu Liao, and Shu X Zhou, and Jing F Wang, and Yu L Zhang
January 2009, Journal of the American College of Cardiology,
Murtuza Shahid, and Run L Sun, and Yu Liu, and Jin L Bao, and Can X Huang, and Yu Liao, and Shu X Zhou, and Jing F Wang, and Yu L Zhang
November 2022, Medicine,
Murtuza Shahid, and Run L Sun, and Yu Liu, and Jin L Bao, and Can X Huang, and Yu Liao, and Shu X Zhou, and Jing F Wang, and Yu L Zhang
November 2020, Coronary artery disease,
Murtuza Shahid, and Run L Sun, and Yu Liu, and Jin L Bao, and Can X Huang, and Yu Liao, and Shu X Zhou, and Jing F Wang, and Yu L Zhang
January 2021, Cardiology research and practice,
Murtuza Shahid, and Run L Sun, and Yu Liu, and Jin L Bao, and Can X Huang, and Yu Liao, and Shu X Zhou, and Jing F Wang, and Yu L Zhang
December 2000, Current opinion in lipidology,
Copied contents to your clipboard!